Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - ...

Sanofi has agreed to invest up to $25m in Adagene, which will enable the latter to fund its research and development (R&D) ...

Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...

Adagene Inc. (NASDAQ:ADAG) saw its shares rise by 6.1% on Tuesday after the biotech firm revealed a strategic investment deal ...

Sino-American antibody company Adagene (Nasdaq: ADAG) has announced a strategic investment and option exercise by Sanofi ...

Potential Positives. Sanofi has agreed to a strategic investment of up to US$25 million, which will enhance Adagene's financial stability and extend its cash runway into 2027.

Sanofi agreed to invest up to $25 million in the clinical-stage biotechnology company. Adagene said it plans to use the proceeds to fund its research and development activities, including clinical ...

Investing.com -- Adagene Inc. (NASDAQ: ADAG) stock surged 6.1% after the antibody-based therapeutics company announced a strategic investment of up to $25 million from Sanofi (EPA: SASY) and the ...

Sanofi has also exercised its option to select a third SAFEbody discovery program, utilizing Adagene’s proprietary masking technology and antibody engineering expertise.

American depositary receipts of Adagene rose 15% in premarket trading following an investment from Sanofi. ADRs were trading around $2.24. The stock is down 2% on the year. Sanofi agreed to invest ...

The company reported audited cash and cash equivalents of $85.2 million as of December 31, 2024. Combined with Sanofi’s investment, Adagene expects to fund planned operations into 2027.